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Abstract. Uveal melanoma is the most prevalent primary
intraocular cancer in adults. Although it accounts for only
5% of all melanomas, it is responsible for 13% of deaths due
to this type of cancer. A wide variety of therapeutic options
of primary tumor is available and progress in its
management is noticeable. The fact still remains, however,
that almost half of patients develop metastases which may
be due to practically undetectable cancer spread present as
early as at diagnosis of the primary focus. Metastatic disease
is uniformly fatal despite systemic therapy. Prediction of
metastasis is crucial for prognosis. It also allows targeting
of emerging new therapeutic methods to the appropriate
group of patients. The Authors reviewed literature
concerning epidemiology and etiopathogenesis of uveal
melanoma, and its clinical, histopathological and
cytogenetic prognosticators.
Uveal melanoma (UM) is a potentially lethal cancer but
factors determining unfavorable course of this disease are
still unknown. Severe form of UM requires intense therapy.
On the other hand, unreasonable treatment affects negatively
the quality of vision and whole life of the patients. The
decision on the scope of treatment needs to precede
uniformly fatal metastatic spread. Consideration of clinical,
histopathological and cytogenetical prognosticators help to
define group of patients with different prognosis in UM.
Epidemiology and Etiopathogenesis
Uveal melanoma (UM) is the most prevalent type of primary
intraocular neoplasm in adults (1). In the European
population, the incidence of UM ranges from under 2 to over
8 per million annually and is similar to the mean value of
4.3 per million for the USA. No significant changes of UM
prevalence have been observed in either of the populations
in long-term clinical observations (1-4). The incidence rate
increases with age and tends to plateau among adults 75
years and older. The mean age at UM diagnosis is 58-61.4
years (±15 years; range 3-100 years) and has increased
gradually over the past 40 years (5, 6). Studies report slightly
a higher incidence rate among men (2, 3, 5).
Most cases of UM occur in the White population (95-
98%) (3, 5-7). In the European population, a latitudinal
gradient of incidence was reported: in the south of Europe,
the rate was lowest and increased towards the north to reach
the highest values in Scotland and Scandinavian countries
(2). In the USA, no geographical variations were noted
except for in Hawaii where the incidence rate was
considerably lower (one per million) (3). The authors of both
reports pointed to the protective role of increased skin
pigmentation and darker eye color as the cause of the
observed correlations.
Despite progress in the management of primary tumor, the
mortality rate for UM has remained high (1, 8). Although UM
accounts for only 5% of all melanomas, it is responsible for
13% of deaths due to this type of tumor (4, 9). A wide variety
of therapeutic options, namely brachytherapy, proton beam
irradiation, transpupillary thermotherapy, photocoagulation,
local resection, endoresection, and enucleation, is available.
The fact still remains, however, that almost half of patients
with UM develop metastases, which may be due to
practically undetectable neoplasm spread present as early as
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at diagnosis of the primary focus (10). UM spreads through
the blood, and the liver is the preferred metastatic site (89%),
followed by the lungs (29%) and bones (17%) (11). Uveal
melanoma-related mortality reaches 31% by 5 years from the
diagnosis of UM, and 45%, 49% and 52% by 15, 25 and 35
years, respectively (12). Therefore, it seems that the
oncological follow-up should span at least 15 years after
completion of primary tumor treatment. 
It is common practice that all patients with UM are
screened for liver metastasis every 6 or 12 months using
imaging techniques or liver function tests, even though
adjuvant therapy fails to yield satisfactory therapeutic effect
and metastasis can hardly ever be managed by surgery (13-
16), liver chemoembolization (17-19) or immunotherapy (20).
While the 5-year relative survival among patients with
UM ranges from 77% to 84% (21), the mean survival time
following detection of UM metastasis is 3-4 months, with
subsequent 1-year survival of 10-15%, and only 1% of
patients live longer than 5 years after diagnosis (11, 22). In
patients who developed primary metastasis to sites other than
the liver, the mean survival time is normally longer and is
19-28 months with statistical 1-year survival of 76% (23-25).
Etiopathogenesis of UM remains unclear. Guanine
nucleotide-binding protein subunit alpha-Q (GNAQ) and
guanine nucleotide-binding protein subunit alpha-11 (GNA11)
gene mutations have been shown to be the first element in the
chain of changes that lead to the development of most cases
of UM (26, 27), and to be related with the activation of
mitogen-activated protein kinase (MAPK) pathway and other
intracellular signaling pathways (28, 29). It was demonstrated
that the co-existence of GNAQ mutation and  breast cancer 1-
associated protein 1 (BAP1) gene mutation is associated with
increased metastatic potential of UM. Families with BAP1
germline mutations are more susceptible to a number of
cancer types including choroidal melanoma (30-32), however,
BAP1 mutations are usually somatic, and the prevalence of
hereditary UM is lower than 1% (33). The role of
environmental factors in UM pathogenesis is still elusive,
although sunlight exposure has been implicated in
development of GNAQ/GNA11 mutation (34-36).
Clinical Prognosticators
The clinical and histopathological features that are predictive
of poor prognosis of UM are: older age, ciliary body
location, large basal diameter and thickness of tumor, the
presence of closed connective tissue loops, epithelioid cell
type, high mitotic rate, extraocular tumor extension, brown
color of the tumor, presence of subretinal fluid and
intraocular hemorrhage (6, 37, 38).
i. Patient age at diagnosis. The work by Shields et al., which
investigated 8,033 cases, is the largest study available to date
discussing the prognostic significance of age in UM (39). It
was shown that 1% of UM is diagnosed in patients below 20
years of age, 53% those aged 21-60 years and 45% in
patients over 60 years old. Young patients are relatively often
diagnosed with tumors of the iris (21%), while in all age
groups, UM is most commonly located in the posterior part
of the uvea (71, 91 and 90%, respectively) (39).
Mean basal tumor diameter and thickness, as well as the
frequency of extrascleral extension, were shown to increase
with age, similarly to the rate of occurrence of metastases
and tumor-related mortality (39).
Metastasis at 3, 5, 10 and 20 years was detected in
patients under 20 years old in 1.7%, 8.8%, 8.8% and 20.2%
of cases, respectively, in the group aged 21-60 years in 6.2%,
12.2%, 23.0% and 34.2% of cases, and in those over 60
years old in 11.1%, 18.7%, 27.7% and 38.8% of cases (39).
The corresponding 3-, 5-, 10- and 20-year tumor-related
mortality rates were 0%, 2.2%, 5.1% and 17.0%, 3.2%,
6.2%, 11.0% and 16.6%, and 6.5%, 11.0%, 15.9% and
20.1%, respectively (39).
ii. Tumor location. Although UM may be potentially
diagnosed on clinical examination with almost 100%
accuracy (34), in many patients, the tumor is missed or
misdiagnosed (40). A lack of subjective symptoms in nearly
one-third of patients, comorbid eye disorders, or diseases
which hinder diagnosis, as well as incorrect technique (e.g.
examination without mydriasis) may be the root of some of
the problems. Tumor location may also make diagnosis more
difficult: 3.5% of UM occurs in the iris, 6.1% in the ciliary
body, and 90.3% in the posterior part of the uvea (6).
UM located in the ciliary body initially does not result in
visual impairment and often remains undiagnosed until it is
large enough to distort the iris or emerge from beneath its
edge and induce other structural and functional changes
within the eyeball. Sometimes it is diagnosed only after
extraocular spread is observed. Even though ciliary body
location of UM is an unfavorable prognostic factor
irrespective of its size or cellular type (41), it was
demonstrated that UM involving the ciliary body is more
likely to comprise epithelioid cells and have a greater
diameter than that confined to the posterior part of the uvea
(42). It is assumed that an anatomical location that impedes
early diagnosis, as well as high mobility of the ciliary body
due to the contractions of the ciliary muscle, the numerous
vessels and a likely occurrence of extravascular matrix
patterns of poor prognosis in this area may be associated
with higher metastatic potential of UM (42, 43). Delayed
treatment often necessitates a more radical form of treatment
i.e. enucleation of the eye (40).
UM that originates from the iris is associated with better
prognosis, which may stem from the fact that such tumors are
more easily identified and, as a result, treatment is applied
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much sooner (41). Clinical features that affect the metastatic
potential of UM of the iris are age at diagnosis, infiltration of
the anterior chamber angle, extraocular extension, elevated
intraocular pressure and prior surgeries (44).
Tumors of the posterior part of the uvea, which directly or
indirectly (e.g. due to concomitant retinal detachment) affect
the macula, may induce blurry and distorted vision. It seems
that these symptoms should contribute to cancer being
diagnosed earlier than in the case of ciliary location.
However, in the study by Shields et al., a relatively small
difference was reported as regards patient age at diagnosis
(6). For UM of the iris, ciliary body and posterior part of the
uvea, it  was reported as 50, 59 and 58 years, respectively.
At diagnosis, the mean thickness of tumor located in the
iris was 2.7 mm,  6.6 mm in the ciliary body, 5.5 mm in the
posterior part of the uvea, and  the mean largest basal
diameter was 6.5 mm, 11.7 mm, and 11.3 mm, respectively.
At 3 years, metastases  were observed in 0.5%, 12%, 8% of
cases, respectively, at 5 years in 4.1%, 19%, 15%, and at 10
years in 6.9%, 33%, 25% (6).
5-Year mortality for  UM of the ciliary body was reported
to be 22-53% and for  that of the posterior part of the uvea
14%, and 10-year mortality for iris UM was 5-6% (41).
iii. Tumor size. Meta-analysis of Diener-West et al. attempted
to provide systematic results of eight studies on mortality
rates following enucleation for UM (45). For small (<3 mm-
thick and <10 mm in basal diameter), medium (3 to 8 mm-
thick and <15 mm in basal diameter) and large (>8 mm-thick
and >15 mm in basal diameter) tumors, 5-year overall
mortality was 16%, 32% and 53%, respectively.
Shields et al. adopted tumor thickness as the criterion of
tumor size, as they decided that the acquisition of this
dimension by ultrasonography ensures higher precision than
the measurement of basal tumor diameter (6). They
concluded that small tumors (0 to 3.0 mm-thick) metastasize
at 5, 10 and 20 years in 6%, 12% and 20% of cases
respectively, medium (3.1 to 8.0 mm-thick) tumors in 14%,
26% and 37%, and large (>8.0 mm-thick) tumors in 35%,
49% and 67%. Every 1 mm increment in thickness of
primary UM equated to a 5% higher probability of metastasis
development and e.g. for a 4 to 5 mm-thick tumor, the
probability was approximately 25%, while for one 7 to 
8 mm-thick, it increased to 40% (6).
In another study, Shields et al. compared the prognosis for
small tumors (<3 mm-thick) of diffuse (thickness/base ratio
≤20%) and nondiffuse (thickness/base ratio >20%) types
(46); 17% of tumors were diffuse. UM-related metastasis
was detected in 8% and 4% of cases, respectively, at 5 years,
16% and 10% at 10 years, and 19% and 16% at 15 years.
The corresponding UM-related mortality rates were 6% and
2%, 11% and 4%, and 16% and 6%, respectively. This
considerably worse prognosis for patients with diffuse
tumors was even more prominent when tumors up to 2 mm-
thick were analyzed.
Tumor basal diameter and its thickness have been reported
to be strongly correlated with UM prognosis by numerous
authors (38, 47, 48).
iv. Methods of treatment. The aim of the multicenter
Collaborative Ocular Melanoma Study (COMS) was to solve
the problem of selecting the optimum method of treatment
for primary UM (34). The  three-arm study evaluated the
effectiveness of management  of small, medium and large
tumors (1.5 to 2.4 mm-thick and 5-16 mm in diameter, 2.5
to 10 mm-thick and ≤16 mm in diameter, >10 mm-thick and
>16 mm in diameter, respectively).
In the case of large tumors (1,003 patients), the
effectiveness of enucleation was compared to enucleation
with preoperative radiation therapy. 5-Year survival was not
statistically different between the groups and 5-year tumor-
related mortality was 28% and 26%, respectively (34).
For medium tumors (1,317 patients), enucleation was
compared with brachytherapy using iodine-125. The mortality
rate in both groups was almost identical. It should be noted,
however, that ciliary body location tumors and tumors located
near the optic nerve disc which are inaccessible for
brachytherapy were excluded from the COMS (34).
A group of 204 patients diagnosed with a small UM was
entered into a registry and managed with watchful waiting.
5-Year and 8-year cancer-related death was 1% and 3.7%,
respectively (34).
Even though COMS received criticism due to the study
criteria applied, the data collected brought about a shift in
treatment modalities for small and medium tumors towards
vision-preserving therapies.
Similar survival times of patients with primary UM treated
by different methods (34, 41) prove that improving diagnosis
and management of metastasis is vital for prognosis.
Histopathological Prognostic Factors
i. Cell type. The first classification of malignant melanocytic
eye tumors was proposed in 1931 by Callender (49), and
then modified by McLean et al. (50).
The main criterion of division into histologic types of UM
is the morphological subtype of cells as epithelioid or spindle
cell in the tumor. Epithelioid cells have abundant acidophilic
cytoplasm, large round or oval nuclei, a high nuclear-to-
cytoplasmic ratio and a high number of mitotic figures. They
are large, polymorphous and have a tendency towards
discohesion. Their presence in the tumor is strictly related
with considerably higher UM metastasis development
probability and higher mortality rate (38, 51).
Spindle cells are elongated with large nuclei and scant
cytoplasm (low nuclear -to-cytoplasmic ratio). They are
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uniformly and densely arranged and may form palisades.
There are very few cells with prominent nucleoli, and hardly
any mitotic figures are observed.
The epithelioid cell type comprises approximately 3-5%
of all UM and is associated with the least favorable
prognosis. The 15-year mortality rate among patients
diagnosed with epithelioid cell type UM is 75% (41).
Spindle cell type accounts for approximately 40% of all
UM. The 15-year mortality rate is 20% (41).
Up to 50% of all UM are the most frequent mixed type.
The 15-year mortality rate is approximately 60% but
considerable differences are observed depending on the
percentage of epithelioid and spindle cells (41).
ii. Mitotic activity. McLean et al. demonstrated a strong
association between the number of mitoses observed per 40
high-power fields (HPF) and prognosis in patients with UM
(51). Tumors of low mitotic activity (0-1/40 HPF) were
associated with 6-year mortality rate of 15-23%, those with
medium activity (2-8/40 HPF) 40-47%, and those with high
activity (9-48/40 HPF) 56%. In a study by Damato et al.,
there was a statistically significant correlation between
tumors with mitotic activity higher than 4/40 HPF and the
development of metastasis and metastasis-related mortality
(38). Angi et al. demonstrated that the conventional mitotic
activity count that involves counting mitotic figures in a
routine hematoxylin and eosin staining depends on the
experience of the person performing the count and carries an
error of underestimation (52). They demonstrated that the
use of phospho-histone H3 (Ser10) mitotic marker results in
a higher number of mitoses being recognized in the analyzed
material, increasing the reproducibility of counting and
makes it more independent of the examiner’s experience. 
iii. Tumor-infiltrating lymphocytes (TILs) - lymphocytic
inflammatory infiltration. Globally, inflammatory infiltration
in UM, which involves an increased number of lymphocytes
and macrophages and human leukocyte antigen (HLA) I and
HLA II expression, is associated with worse prognosis (53).
Lymphocytic infiltration is observed in 17% of cases of
UM (54), more frequently in ciliary body UM than in tumors
confined to the posterior part of the uvea (42). TILs in UM
are mainly suppressor/cytotoxic T-lymphocytes (CD8+), to a
lesser degree T-helper lymphocytes (CD4+), as well as
regulatory T-lymphocytes [CD3+ forkhead box P3
(FOXP3)+] (55, 56).
Lang et al. showed that brisk and non-brisk lymphocytic
infiltration was associated with mixed and epithelioid cell UM
(93.3% and 78.4%, respectively) (54). However, no statistically
significant difference in mortality was demonstrated in their
study in relation to TILs presence or absence in UM. In a study
by de la Cruz et al. brisk TILs (defined as the presence of 100
or more lymphocytes per 20 HPF) was observed in 12.4% of
UM (57). A group of 125 tumors with brisk TILs was
compared with a control group with less intense inflammatory
infiltration and it was shown that TILs are a significant factor
of adverse prognosis in patients with UM. The 15-year
survival rate in the group of patients with low lymphocytic
infiltration is up to 69.6% and falls to 36.7% in the group
with high infiltration. The authors suggested that the presence
of TILs results from the general response of the
immunological system to melanoma cells in the circulatory
system, which act as specific circulating tumor cells (CTCs)
that are a potential source of metastasis. In this approach,
TILs identified in the primary UM should be considered
indirect evidence of systemic cancer spread (57).
Better prognosis observed with down-regulation of HLA
class I on UM cells is explained by their higher susceptibility
to natural killer lymphocytes (53). 
The influence of T-regulatory lymphocytes on the course
of UM and prognosis remains unclear. There are some
hypotheses that they may be involved in the induction of
immunosuppressive mechanisms that block the proper
response to the tumor (53).
Tumor-associated macrophages (TAMs) of varying grades
also occur in UM with infiltration being low in 17%,
moderate in 51%, and pronounced in 32% (58). The
percentage of macrophages in lymphocytic infiltration is
correlated with metastasis-related mortality and female sex,
largest basal diameter of the tumor, epithelioid cell type,
strong pigmentation and microvascular density (58). Most of
the TAMs that are found in UM belong to the M2 subgroup
which supports tissue remodeling and angiogenesis (59). 
iv. Extravascular matrix pattern. Folberg et al. described nine
morphological patterns of UM extravascular matrix (60). They
found that the patterns are created by the tumor vessels, which
gave rise to controversies (61, 62). Irrespective of the ongoing
research into the origin of the connective tissue septal
networks (containing blood vessels) between the complexes
of tumor cells observed in periodic acid-Schiff staining,
Folberg et al. demonstrated that their arrangement affects
prognosis (60). They described two patterns, namely loops,
and networks, whose common feature is the presence of at
least one closed loop. Then they compared the patterns that
did not contain a closed loop with the ones that did. During
the follow-up, UM ended in the death of two patients in the
first group (19 tumors) and of 18 patients in the second group
(21 tumors), respectively. Mäkitie et al. demonstrated that the
extravascular matrix pattern may be determined in 80% of
UM cases acquired as a result of enucleation (63). The loop
pattern was identified in 60% of cases and the network pattern
in 35%. Ten-year UM-related survival was statistically worse
for those with network pattern tumors, compared with those
loops without networks and those with no loops (0.41 versus
0.53 versus 0.83; p<0.0001), and the prognosis for tumors
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with a network pattern and those with loops without networks
did not differ significantly. 
Rummelt et al. stated the strong association of ciliary
body UM with death from  metastatic melanoma (p=0.0006),
along with the following extravascular matrix patterns:
parallel vessels (p=0.0043), parallel with cross-linking
(p=0.0001), arcs (p=0.0028), arcs with branching, loops and
network (p=0.0001 each). The aggressive behavior of ciliary
body melanomas appears to be related to the tendency for
vascular networks to develop in this location. Regardless of
location, ciliary body or choroid, the presence of vascular
networks shortens survival (42).
Connective tissue septa that form extravascular matrix
patterns associated with worse prognosis were found to
contain a higher number of blood vessels (62). This means
non-invasive methods of assessment vascularization  for UM
prognosis might be applied (64, 65). Characteristic
extravascular matrix patterns are also reported in UM
metastases, irrespective of their location (66). Further studies
concerning the origin and role of tissues that form
extravascular matrix patterns may help improve UM therapy.
v. Degree of pigmentation. McLean et al. showed that the
degree of tumor pigmentation has no prognostic value for
patients with tumors containing epithelioid cells (51). On the
other hand, prognostic value assigned to the amount of
pigment in spindle-cell tumors may to a large extent be
attributed to artifacts produced in the course of preparation
of histopathological specimen. Accurate definition of the
prognostic significance of pigmentation warrants further
histopathological and statistical analysis.
vi. Extrascleral extension. Extrascleral extension may occur
via aqueous channels (29.8%), ciliary arteries (27.4%),
vortex veins (18.5%), ciliary nerves (8.9%) or the optic
nerve (0.8%). In 10.4% of patients, the tumor spreads to the
extraocular space simultaneously via a variety of routes.
Extrascleral extension is strongly correlated with
involvement of the anterior chamber angle, basal diameter of
the tumor, the presence of epithelioid cells, closed
connective tissue loops and monosomy 3. Interestingly,
extraocular extension along aqueous drainage channels,
which is the most frequent route, correlated positively with
anterior chamber angle involvement and inversely with basal
tumor diameter and tumor thickness.
Metastasis-related mortality is higher irrespective of the
route of extrascleral spread route and was not found to
correlate with the size of extraocular tumor. It seems that
extrascleral tumor extension may be considered incidental to
tumor malignancy, and in the case of UM of the posterior
part of the uvea, also to its stage of advancement rather than
being an independent cause of development of distant
metastases (37).
In a study by Schmittel et al., 5-year metastasis-free
survival in patients with extraocular extension of UM was
28% versus 80.6% among patients without extraocular tumor
growth (48). The mean time to metastasis development in
patients with extraocular tumor growth was 35 months. The
5-year survival was 50% among patients with extraocular
tumor growth and 83.3% among those without.
Cytogenetic abnormalities as potential
prognosticators
The correlation between UM and changes within
chromosomes 1, 3, 6 and 8 was noted a long time ago. The
most frequent aberrations include the loss in the short arm
of chromosome 1 (27%); losses in the short arm (45%), and
long arm (49%) of chromosome 3; loss in the long arm
(39%), and gain in the short arm (39%) of chromosome 6;
loss in the short arm (20%), and gain in the long arm 8
(69%) and the short arm (20%) of chromosome 8 (67-69).
Hoglund et al. confirmed the existence of two independent
cytogenetic pathways in UM that are of key importance for
UM progression (68). The early alteration of one of them is
the occurrence of monosomy 3, and subsequent 8q+, 8p- and
1p- aberrations. In the second one, gain of the short arm of
chromosome 6 and subsequent 6q-, 8q+ imbalances occur.
Co-occurrence of monosomy 3 and 6p imbalance is reported
in only 4% of UM, while in 18% of primary tumors, the
proper number of chromosomes 3 and 6p was observed (69).
Furthermore, similar cytogenetic aberrations were observed
in cutaneous melanoma. This is intriguing considering the
many discrepancies identified clinically in the course of
melanoma in both locations (68). Taking into account clinical
data, it was shown that the subgroup of patients with
monosomy 3 and normal short arm of chromosome 6 was
associated with the highest probability of development of
metastatic foci. Indirect risk was identified for the subgroup
with disomy 3 and 6p+, and the lowest for the subgroup
without aberrations in 3 and 6p (69).
Monosomy 3 is detected in approximately 50% of primary
UM. It is an independent unfavorable prognostic factor of
shorter survival and a factor of higher risk of developing
organ metastasis (more prominent than any other clinical
factor) (70). In a study by Prescher et al., during the follow-
up period UM metastasis was detected in 57% patients with
confirmed monosomy 3 in the primary tumor (70). The mean
survival in this subgroup was less than 6 months from the
diagnosis of metastasis. The authors also suggested
concomitant involvement of several genes located on
chromosome 3 in the changes occurring in the course of UM
progression and the secondary development of distant
metastases. Suppressor genes, whose inactivation conditions
the development of UM, may be located both on 3p and 3q,
which might explain a correlation with the loss of the entire
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(normal) chromosome (70, 71) that is more frequent here
than in other cancer types.
The selection of examination technique is an important
issue in the search for monosomy 3. Isodysomy 3 may occur
in the UM progression as a result of the loss of one
chromosome 3, and the subsequent duplication of the faulty
chromosome (72). Some of the methods of karyotype
evaluation only allow detection of “standard” monosomy,
which leads to the underestimation of the number of faulty
cells. Techniques based on the analysis of the number of
chromosomes, such as fluorescence in situ hybridization and
comparative genomic hybridization, have lower sensitivity
and specificity in the prognosis of UM metastasis than
methods allowing for the detection of the loss of
heterozygosity of chromosome 3, such as single nucleotide
polymorphism (73, 74).
It must be stressed that although a strong correlation
between monosomy 3 and prognosis in UM was confirmed,
this factor cannot be the only prognostic criterion. Clinical
assessment is of key importance for the precise prognostic
stratification of patients with UM, with special attention paid
to the basal tumor diameter and identification of the
histopathological type of UM. Genetic typing should also allow
for other mutations and aberrations specific for UM (38, 74). 
8q+ Chromosomal aberration is the one most frequently
observed in UM. Therefore, the order of occurrence of
monosomy 3 and 8q+ in the course of UM, as well as the
role of either of these as the tumor-initiating aberration, are
still controversial (69, 75). The number of copies of the long
arm of chromosome 8 may increase as a result of its gain
(8q+/8pnl) and as a result of trisomy 8 (8q+/8p+) or
isochromosome 8 (8q+/8p-) that in UM occurs almost
exclusively with monosomy 3 (69). Irrespective of the
chronology of changes, we know that 8q+ is more frequently
found in patients with monosomy 3, which worsens
prognosis depending on the number of copies of the long
arm of chromosome 8 (69, 75). Monosomy 3 and an
increased number of chromosome 8 are strongly correlated
with the involvement of ciliary body, basal tumor diameter,
epithelioid cell UM, the presence of closed loops, and high
mitotic rate. Furthermore, monosomy of chromosome 3 is
strictly correlated with the presence of extraocular spread
(38). Damato et al. determined that 5-year UM-related
mortality was 6% with no aberrations in chromosomes 3 or
8, 31% with gain of chromosome 8, 40% with monosomy 3,
and 66% with co-existent monosomy 3 and chromosome 8
gain (38). However, the study was only focused on tumors
originating in the posterior part of the uvea.
In UM, changes occur in the genes that are related with
centrosomal function, regulation of the cell cycle and DNA
damage repair i.e. the key processes in maintenance of
genomic integrity. Ataxia telangiectasia and Rad3 related
(ATR) and phosphatase and tensin homolog (PTEN) gene
expression is decreased in UM. Mutations of ATR gene
located on chromosome 3q22 are responsible for microsatellite
instability. Mutations of PTEN tumor-suppressor gene lead to
the loss of genomic integrity via a number of ways. The
occurrence of ATR and PTEN gene damage may partly explain
the gradual increase of aneuploidy in melanoma development
(69). However, Ehlers et al. showed that poor prognosis in
UM is related with early chromosomal alterations rather than
with the subsequent increase in their number (69).
The use of gene-expression profiling by Onken et al. (76)
allowed for identification of 62 discriminating genes in UM.
They were used to divide the analyzed tumors into two
classes. Class 2 tumors had a lower number of genes with
their loci on chromosome 3 and a higher representation of
genes of the long arm of chromosome 8, which was in
agreement with previous studies on chromosomal aberrations
in UM. To determine the prognostic value of the classifier in
UM metastasis, 50 cases were analyzed. The 92-month
survival probability was 95% in class 1 and 31% in class 2.
The prognostic accuracy of molecular classifier superseded
all clinical and histopathological prognostic factors. It should
be noted that half of the tumors were evaluated based on the
sample that corresponded to the size of the material acquired
at biopsy (76). Class 1 was further divided into subclass 1a
and 1b that differed as regards prognosis, with 5-year cancer-
related mortality of 2% and 21% for class 1a and 1b,
respectively, and 72% for class 2 (77). Class 2, associated
with a high risk of developing metastasis, was found to be
correlated with frequent occurrence of BAP1 gene mutation
at the 3p21.3 region. Harbour et al. identified BAP1
mutations in 26 out of 31 (84%) class 2 UM and in only one
out of 26 class 1 UM (78). Class 2 was associated with the
largest basal tumor diameter, poor cellular differentiation and
epithelioid cell tumor, involvement of ciliary body, the
presence of extraocular spread, and closed loops, as well as
the loss of heterozygosity of chromosome 3, increased
aneuploidy, higher mitotic rate and up-regulation of Ki-67
(33). Continuing their studies into molecular classifier of
UM based on gene expression profiling, Onken et al.
proposed that the number of analyzed genes be reduced to
12 discriminating genes and three control genes (79). The
use of polymerase chain reaction has made the evaluation
largely independent from the method of obtaining the
material for testing. Additionally, the authors showed that
heterogeneity of tumor tissue does not have a significant
impact on the result of tests performed on the material
obtained using fine-needle aspiration biopsy. Modifications
of this method help to optimize it for routine clinical
applications and for eye- and vision-sparing therapies. 
Estimating prognosis in clinical practice, particularly in
individual patients, requires prior validation of research
methods (80). The Collaborative Ocular Oncology Group,
which analyzed results from 12 independent research centers,
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showed in its first report that gene-expression profiling
supersedes the evaluation of chromosome 3 and TNM
classification to offer more accurate prognosis as regards the
metastatic potential of UM (81). Gene-expression profiling
allowed UM molecular class to be determined in 97.2% of
cases, of which 61.9% were class 1 and 38.1% class 2.
Throughout the follow-up period (18 months on average),
UM metastases were detected in 1.1% of cases in class 1 and
25.9% in class 2 (81). This allowed a commercially available
test to be introduced into the market (DecisionDx-UM;
Castle Biosciences, Incorporated). It is now used in several
centers (82, 83).
The excellent progress made over the past decade in
molecular biology of UM will enable for further development
of new prognostic tests that will stratify patients into
prognostic subgroups that differ significantly as regards long-
term prognosis and risk of distant metastases with even higher
precision and accuracy. Moreover, advances in molecular
biology may help discover new signaling pathways involved
in UM development, which may pave the way towards new
target drugs for personalized therapy. 
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